度洛西汀联合重复经颅磁刺激治疗老年抑郁障碍患者的效果及对脑源性神经营养因子水平的影响

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (0 KB) HTML (37 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the therapeutic effect of Duloxetine combined with repetitive transcranial magnetic stimulation (rTMS) in the treatment of elderly patients with depressive disorder and its influence on the expression of serum brain neurotrophic factor (BDNF). Methods A total of 60 elderly depressive patients in Qingdao Mental Health Center were selected from December 2016 to August 2017. All patients were divided into the true stimulation group and the pseudo stimulation group according to random number table methods, 30 cases in each group. Patients in the true stimulation group were treated with Duloxetine and combined with rTMS, while patients in the pseudo stimulation group were treated with Duloxetine and combined with rTMS pseudo stimulation. The 17-item Hamilton depression rating scale (HAMD-17) and the repeatable battery for the assessment of neuropsychological status (RBANS) were compared and analyzed before treatment and 8 weeks after treatment. Fasting blood samples were taken on the second day of admission and the morning of the 8th weekend of treatment to detect the level of serum BDNF. Results At the end of 8 weeks of treatment, the HAMD-17 scores of the two groups were lower than those before treatment, and the HAMD-17 score of the true stimulation group was lower than that of the pseudo stimulation group at the end of 8 weeks of treatment, the differences were statistically significant (P＜0.05). The RBANS scores of the two groups at the end of 8 weeks of treatment were higher than those before treatment, and the RBANS scores of the real stimulation group at the end of 8 weeks of treatment were higher than those of the pseudo stimulation group, the differences were statistically significant (P＜0.05). The levels of BDNF in blood samples of the two groups at the end of 8 weeks of treatment were higher than those before treatment, and the level of BDNF in blood samples of the real stimulation group at the end of 8 weeks of treatment was higher than that of the pseudo stimulation group, the differences were statistically significant (P＜0.05). Conclusion Duloxetine combined with low rTMS can effectively improve cognitive function and the symptoms of depression in the treatment of depression in older patients.

Key words： Duloxetine Repetitive transcranial magnetic stimulation Depression Brain derived neurotrophic factor;Cognitive function

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GAO Xiao
	ZHOU Tian-tian
	LIU Shan
	ZHENG Zhan-jie

Cite this article:

GAO Xiao,ZHOU Tian-tian,LIU Shan, et al. Effect of Duloxetine combined with repetitive transcranial magnetic stimulation in the treatment of elderly patients with depressive disorder and its influence on the level of brain-derived neurotrophic factor[J]. 中国当代医药, 2021, 28(28): 96-99.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I28/96

[1]	王永军，孙丽丽，贾建军.老年抑郁症与认知功能障碍研究进展.中华老年心脑血管病杂志[J]，2019，21（7）：777-779.
[2]	Xu X，Wei Y，Guo Q，et al.Pharmacological characterization of H05，a novel serotonin and noradrenaline reuptake inhibitor with moderate 5-HT2A antagonist activity for the treatment of depression[J].Pharmacol Exp Ther，2018，365（3）：624-635.
[7]	世界卫生组织.ICD-10 精神与行为障碍分类临床描述与诊断要点[M].范肖东，汪向东，于欣，等，译.北京：人民卫生出版社，1993.
[10]	李涛，徐一峰.精神科医生手册[M].北京：人民卫生出版社，2017：124-125.
[14]	Peng W，Mao L，Yin D，et al.Functional network changes in the hippocampus contribute to depressive symptoms in epilepsy[J].Seizure，2018，60：16-22.
[3]	Hendrikse J，Kandola A，Coxon J，et al.Combining aerobic exercise and repetitive transcranial magnetic stimulation to improve brain function in health and disease[J].Neurosci Biobehav Rev，2017，83：11-20.
[4]	Lefaucheur JP，Aleman A，Baeken C，et al.Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation （rTMS）：an update （2014-2018）[J].Clin Neurophysiol，2020，131（2）：474-528.
[5]	Peng S，Li W，Lv L，et al.BDNF as a biomarker in diagnosis and evaluation of treatment for schizophrenia and depression[J].Discov Med，2018，26（143）：127-136.
[6]	McIsaac W，Ferguson AV.Glucose concentrations modulate brain-derived neurotrophic factor responsiveness of neurones in the paraventricular nucleus of the hypothalamus[J].Neuroendocrinol，2017，29（4）：12464.
[8]	Müller MJ，Dragicevic A.Standardized rater training for the Hamilton Depression Rating Scale （HAMD-17） in psychiatric novices[J].Affect Disord，2003，77（1）：65-69.
[9]	Randolph C，Tierney MC，Mohr E，et al.The repeatable battery for the assessment of neuropsychological status （RBANS）：preliminary clinical validity[J].Clin Exp Neurop-sychol，1998，20（3）：310-319.
[11]	Liu L，Gou Z，Zuo J.Social support mediates loneliness and depression in elderly people[J].Health Psychol，2016，21（5）：750-758.
[12]	Greer TL，Sunderajan P，Grannemann BD，et al.Does duloxetine improve cognitive function independently of its antide-pressant effect in patients with major depressive disorder and subjective reports of cognitive dysfunction?[J].Depress Res Treat，2014，2014：627863.
[13]	McIntyre RS，Lee Y.Cognition in major depressive disorder：a "Systemically Important Functional Index" （SIFI）[J].Curr Opin Psychiatry，2016，29（1）：48-55.
[15]	Botteron KN，Raichle ME，Drevets WC，et al.Volumetric reduction in left subgenual prefrontal cortex in early onset depression[J].Biol Psychiatry，2002，51（4）：342-344.
[16]	王强，毕昆，花玲玲，等.前额叶-边缘环路theta 波功能连接对抑郁症的识别作用[J].临床精神医学杂志，2018，28（3）：7-10.
[17]	Kozel FA，Johnson KA，Nahas Z，et al.Fractional anisotropy changes after several weeks of daily left high-frequency repetitive transcranial magnetic stimulation of the prefrontal cortex to treat major depression[J].ECT，2011，27（1）：5-10.
[18]	Jkholm C，Monteggia LM.BDNF-α key transducer of antidepressant effects[J].Neuropharmacology，2016，102：72-79.